 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...1213141516171819202122...266267» |
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5793;
These results suggest an unfavorable correlation between lung and liver metastasis and the ICI response. Further biomolecular analysis will be provided in the future.
- Predictors of receiving targeted treatment among eligible patients with metastatic colorectal cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5737;
Our findings highlight the significance of genetic counseling in facilitating access to targeted therapies, and the stark gap in uptake among minority patients. These results can inform strategies to increase access to these treatments.
- Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5689;
P1/2
A significant proportion received subsequent lines of therapy post ICI, and exploration of ORR and PFS to next lines of therapy is of interest. Clinical trial information: NCT02538510 and NCT03749460.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Characteristics of hospital admission during checkpoint-inhibition therapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5629;
6% is comparable to the literature. There was a disproportionate admission of patients with immune-related colitis and hypophysitis compared to the prevalence described under ICI.
- Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5623;
In patients who developed irAEs, we found a significant elevation in ITAC, a chemokine induced by IFN-gamma that attracts activated T cells. Other inflammatory cytokines such as IL-6, IL-13, IL-17, and MIP-1b trended towards significance, likely due to the small sample size.
- Immune checkpoint inhibitor-related reproductive adverse effects: A pharmacovigilance analysis based on the FAERS database. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5613;
Additional therapies could change the risk of irRAEs. Despite the current lack of high-quality clinical data on this topic, it is reasonable to inform patients about the plausible risk of irRAEs.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5598;
Compared to standard flat dosing, weight-based dosing of ICI was associated with a trend towards lower iRAE in patients < 50 Kgs without a difference in survival. These results urge the oncology community to consider the potential financial toxicity savings if weight-based dosing of ICI is adopted more broadly in underweight patients without negatively impacting outcomes, large scale and prospective studies are needed to support this hypothesis.
- Seasonal patterns in immunotherapy outcomes. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5564;
While VD deficiency and VD supplementation were associated with OS, season of ICI initiation was not. These results provide reassurance the OS benefits of ICIs remain similar irrespective of time of year of initiation despite seasonal factors that may influence the immune system.
- Zejula (niraparib) / GSK, J&J
Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5320;
P1/2
Sample size greatly limited adjustment for potential confounders and these results are hypothesis generating only. >(OS = overall survival; PFS = progression-free survival).
- Induction immunotherapy-based regimens followed by palliative CCRT may lead to conversion surgery in selected patients and boost survival for stage IV ESCC. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5259;
Maintenance metronomic UFUR with anti-PD1 may also be beneficial. Afatinib with anti-PD1 could be a good option for (1)frontline treatment for double cancers or CT-unfit patients; (2)salvage treatment in later lines, even failing KN590 or CM648.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Mucosal melanoma treatment patterns and outcomes in real clinical practice: Single institution experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4970;
Mucosal melanoma remains an under-researched malignancy. There is a critical need for prospective, randomized trials to explore more effective treatment options for patients with this condition.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4965;
Background: Perioperative pembrolizumab to advanced melanoma, as shown SWOG S1801 trial, was associated with a longer event-free survival (EFS) than those who received adjuvant pembrolizumab (EFS at 2y: 72% vs 49%, respectively). Neoadjuvant N3+I1 seems to have similar EFS compared to SWOG S1801, but numerically more MPR rate and fewer events of progression, relapse and/or death.
- Immunotherapy toxicity prediction in patients with melanoma using machine learning algorithms. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4957;
Key predictors of toxicity included increasing age, female gender and not receiving Nivolumab in the setting of both adjuvant and palliative intent. Future work will aim to externally validate these models in other centers.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant immunotherapy in clinical stage III melanoma: Real life experience in the community setting. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4951;
A discrepancy was detected between pathologic and radiologic responses. Colitis was the most common grade 3 and 4 toxicity.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4949;
A retrospective observational cohort study was performed for patients age > 18 who died after treatment for advanced melanoma with anti-PD1 therapy or ipilimumab + nivolumab (Ipi/Nivo) at Yale Cancer Center (YCC) between 1/2009 and 6/2023. The majority of deaths were a consequence of metastatic melanoma, with the most common causes including FTT, respiratory failure, and infection.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4943;
However, outcomes are similar in pts treated with PD-1i who have a CR. Further, in older pts and pts with BRAFmut positive disease the benefit of ipi/nivo over PD-1i is less clear.
- Responses to immune checkpoint inhibitor therapy in NF1 mutated cutaneous melanoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4920;
NF1 mutated melanoma appears to have high rates of radiographic responses to ICI therapy. Prospective validation of this finding, particularly in patients with CNS metastasis, is warranted.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Correlation of previous local vaccination site "flares" during immunotherapy for metastatic melanoma with complete responses to therapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4918;
Evidence of prior localized vaccination "flare" may be a biomarker for a complete immunologic response in pts with metastatic disease treated with immunotherapy. ICI targeting CTLA-4 and/or PD-1 both triggered this localized vaccination site response, suggesting that T cell memory and immunologic activation against melanoma antigens translate into clinical responses.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Screening for ocular toxicities of immunotherapy in a real-world population. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4870;
Ocular screening for IOI identified early, often asymptomatic toxicities that could progress to permanent visual disability. Further evaluation of dedicated ocular screening is indicated in patients receiving immunotherapy.
- Effect of combinatorial immune checkpoint blockade on myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1?, and interleukin-6: Biochemical implications in cardio-immuno-oncology. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4845;
Moreover, Atezolizumab is actually under study in association with Ipilimumab for therapy of metastatic lung cancer... Data of the present study, although in vitro, indicate that combinatorial immune checkpoint blockade, induce a pro- inflammatory phenotype, thus indicating that these therapies should be closely monitored by the multidisciplinary team consisting of oncologists, cardiologists and immunologists.
- Immune checkpoint inhibitors (ICI): From cancer killers to electrolyte disruptors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4795;
Our study demonstrated that there is correlation between ICI use and electrolyte imbalance. Providers should be vigilant about the potential electrolyte abnormalities when treating patients with ICI therapy.
- Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4793;
In this prospective surveillance study, new cardiomyopathy was observed after ICI treatment, although the incidence was low. Larger studies are needed to confirm these findings.
- Yervoy (ipilimumab) / BMS
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4611;
In a single NCI-CC review of ICI use, EOC had no difference in ?grade 3 irAEs or in specific irAEs relative to older adults. Within EOCs, those who experienced a significant irAE were more likely to have received Ipilimumab or 2+ ICIs and were less likely to obtain a response to treatment, although mortality was not different.
- Avastin (bevacizumab) / Roche
Real-world outcomes and molecular correlates of incorporating immunotherapy (IO) and bevacizumab (Bev) in treating patients with peritoneal mesothelioma (PeM): A comparative analysis with pleural mesothelioma (PM). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4405;
Notably, addition of Bev did not appear to improve outcomes in PeM, in contrast to PM. These results highlight variances in clinical utility/value of these therapies.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4277;
Adverse events in both age groups were comparable but overall higher in NI arm in both younger and elderly patients. OS estimates were similar for both age groups in N while higher in younger patients compared to older adults in NI.
- Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3964;
P3
NIVO + IPI demonstrated statistically significant OS benefit vs LEN/SOR in pts with previously untreated uHCC, as well as higher ORR and durable responses with a manageable safety profile. These results support this combination as a potential new first-line SOC for uHCC.
- Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3963;
P2
Regorafenib plus pembrolizumab had modest activity in second line after first-line ICI regimens. The safety profile of the combination was consistent with those of either drug.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3954;
P2/3
The addition of nivo to neoadjuvant carboplatin, paclitaxel and radiation does not improve the pCR rate in pts with resected E/GEJ adenocarcinoma. Given the known benefit of the addition of ICI to chemotherapy, a further understanding of the impact of radiation on ICI activity is needed.
- Opdivo (nivolumab) / BMS, Tibsovo (ivosidenib) / Servier, Yervoy (ipilimumab) / BMS
A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma. (Hall A; Poster Bd #: 168b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3926;
P1/2
Upon determination of the RCD, the two expansion cohorts will be initiated to assess the clinical activity of the triplet combination in patients with and without prior ICI. First patient in occurred in November 2023.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma. (Hall A; Poster Bd #: 117) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3867;
P1
Cohort B treatment, which included hydroxychloroquine, incurred more early discontinuations. As designed, neither cohort will advance to Stage 2, highlighting the need for further tailored therapeutic approaches in mPDAC.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma. (Hall A; Poster Bd #: 47) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3798;
P1/2, P2
Our results are encouraging and support further development of this strategy for localized gastric adenocarcinomas. The regimen is safe and potentially generalizable.
- Opdivo (nivolumab) / BMS
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. (Hall A; Poster Bd #: 20) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3773;
P3
NIVO + chemo is the first PD-1 inhibitor/chemo combination to demonstrate long-term efficacy and acceptable safety after 4 yrs of follow up in previously untreated advanced GC/GEJC/EAC. These results are consistent with earlier follow-ups, further supporting NIVO + chemo as a standard 1L treatment in these pts.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648. (Hall A; Poster Bd #: 14) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3768;
P3
After 45 mo of follow-up, NIVO + chemo and NIVO + IPI continued to demonstrate clinically meaningful survival benefit and more durable responses vs chemo, with no new safety signals. These results further support NIVO + chemo and NIVO + IPI as 1L treatment options for advanced ESCC.
- Inlyta (axitinib) / Pfizer, Bavencio (avelumab) / EMD Serono
Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial. (Hall A; Poster Bd #: 420) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3554;
Correlative analysis of the phase II axitinib plus avelumab trial revealed potential biomarkers predictive of combination clinical benefit in ACC, including a gene-expression signature. These findings may guide patient stratification for combinatorial therapy.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Impact of immune-related adverse events (irAE) onset on disease response and survival in patients (pts) with head-neck cancer treated with immune check point inhibitors (ICI). (Hall A; Poster Bd #: 331) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3479;
Although OS was numerically superior in the irAE group, it did not meet statistical significance. ICI re-challenge is feasible in select pts, however further studies are needed to evaluate long term benefit of ICI re-challenge.
- Opdivo (nivolumab) / BMS, Tazverik (tazemetostat) / Eisai, Ipsen, Yervoy (ipilimumab) / BMS
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors. (Hall A; Poster Bd #: 444a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3447;
P1, P1/2,
Key inclusion/exclusion criteria include INI1 loss by immunohistochemistry (IHC) or molecular confirmation; age between 6 mo and 21 yo; no prior immunotherapy; limited corticosteroid; and no history or concern for hematologic malignancy. To date, 4 patients have enrolled, and the study is ongoing in the United States.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101). (Hall A; Poster Bd #: 382a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3381;
P2
Tumor and blood-based biomarkers will be included as exploratory biomarkers. Support: U10CA180821, U10CA180882, U24 CA196171; .
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer. (Hall A; Poster Bd #: 365) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3361;
P2
Unexpectedly, the proteotypes corresponded to three types of clinical outcomes. Clusters 1, 3, and 4 were linked with a lack of benefit from immune therapy.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer (Hall A; Poster Bd #: 361) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3357;
P2
The primary endpoint ORR was not reached. However, we observed an impressive clinical benefit in single patients, which warrants further investigation in order to get more insight into the mechanisms leading to these long-lasting tumor responses.
- Tecentriq (atezolizumab) / Roche
Survival outcomes of patients with extensive-stage small cell lung cancer who received treatment with atezolizumab in combination with carboplatin and etoposide: A propensity score adjusted cohort study. (Hall A; Poster Bd #: 358) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3354;
In the Carbo-E arm, 45 patients (12%) received second-line immune therapy (nivolumab +/- ipilimumab or pembrolizumab). Among pts with ES-SCLC, the addition of atezolizumab to the standard chemotherapy regimen of Carbo-E showed no significant difference in PFS or OS in our real-world study.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. (Hall A; Poster Bd #: 347) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3343;
Older patients had worse prognosis, while there was also a tendency for shorter survival of never smokers and patients with worse ECOG performance status. Further analysis of larger real-world datasets with longer follow-up will be essential to validate these results.
- Efficacy and safety of immunotherapy plus chemotherapy for lung cancer neoadjuvant treatment: A network meta-analysis based on randomized controlled trials. (Hall A; Poster Bd #: 288) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3285;
Concurrent use of nivolumab and ipilimumab resulted in the highest pCR and R0 resection rates. Moreover, for patients with lung cancer, the preliminary evidence supports the value of combining immunotherapy with chemotherapy as a neoadjuvant treatment strategy over chemotherapy alone.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM) (Arie Crown Theater) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3267;
P3
The significant increase in median PFS with the addition of A did not translate into a significant increase in median OS. ABC demonstrated superiority over BC in non-epithelioid cases.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3243;
P3
NADINA is the first phase 3 trial that evaluates neoadj immunotherapy against SOC in melanoma, and is also the first phase 3 trial in oncology evaluating a neoadj regimen consisting of immunotherapy alone. Neoadj IPI+NIVO followed by response-driven adj treatment results in statistically significant improved EFS compared to adj NIVO and should be considered a new SOC treatment in macroscopic stage III melanoma.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
A phase I trial on the intra- and post-operative intracranial administration of ipilimumab and nivolumab in patients with recurrent high-grade glioma. (Hall A; Poster Bd #: 336) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3144;
P1
Neoadj IPI+NIVO followed by response-driven adj treatment results in statistically significant improved EFS compared to adj NIVO and should be considered a new SOC treatment in macroscopic stage III melanoma. In this first in human phase I trial on intracranial CTLA-4/PD-1 blockade in pts with rHGG amenable for resection, intraop iCer and postop iCav admin of NIVO+/- IPI was found to be feasible and safe up to a bi-weekly postop iCav dose of 1 mg IPI + 10 mg NIVO; with encouraging OS results.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). (S406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3104;
This is the first evaluation of the association between mixed response and survival outcomes among patients with various tumors receiving dual checkpoint therapy. Our results suggest that survival outcomes are driven by the "worst" performing lesion; in other words, having an increase in any lesion is associated with worse outcomes, even if not all lesions increase.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Correlations between first cycle toxicity and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609). (Hall A; Poster Bd #: 134) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3056;
P2
Our results suggest that survival outcomes are driven by the "worst" performing lesion; in other words, having an increase in any lesion is associated with worse outcomes, even if not all lesions increase. In this large cohort of patients with rare tumors receiving ipilimumab and nivolumab grade of irAE in the first cycle of therapy was prognostic for survival.
- The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors. (Hall A; Poster Bd #: 127) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3049;
Our study suggests that COVID-19 mRNA vaccines do not increase irAE risk in cancer patients on ICIs. Fully vaccinated patients with breakthrough COVID-19 infections may safely continue ICI treatment without an increased irAE risk.
- nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. (Hall A; Poster Bd #: 101) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3023;
P1/2
HAI of nelitolimod has been well tolerated and associated with encouraging immunologic activity in HCC and ICC. Clinical and biologic activity in cohort C at 4mg is supportive of further enrollment in this cohort.
- mycophenolate mofetil / Generic mfg.
Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors. (Hall A; Poster Bd #: 262) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2880;
MMF was effective for both steroid-refractory and steroid -resistant ir-hepatitis. Early combination with MMF in addition to systemic steroids can lead to a more rapid improvement of ir-hepatitis compared to late combination with MMF consequently reducing the total systemic steroid dosage.